Design and development of a proniosomal transdermal drug delivery system of caffeine for management of migraine: In vitro characterization, 131I-radiolabeling and in vivo biodistribution studies

Aboumanei, Mohamed H.; Mahmoud, Ashgan F.

doi:10.1016/j.procbio.2020.07.018

Cited by 21 publications

(11 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, as other methylxanthines, it binds with adenosine receptors [ 16 ] and induces psychomotor stimulant properties in the brain [ 18 ]. Caffeine is also used in different medical applications, namely in combination with painkillers, e.g., to relieve migraine [ 20 , 21 ], in bronchopulmonary dysplasia treatment [ 22 ], orthostatic hypotension treatment [ 23 ] and the treatment of apnea of prematurity [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Quantification of Caffeine Interactions in Choline Chloride Natural Deep Eutectic Solvents: Solubility Measurements and COSMO-RS-DARE Interpretation

Jeliński¹,

Cysewski²

2022

IJMS

View full text Add to dashboard Cite

Solubility of active pharmaceutical ingredients is an important aspect of drug processing and formulation. Although caffeine was a subject of many studies aiming to quantify saturated solutions, many applied solvents suffer from not being environmentally friendly. This work fills this gap by presenting the results of solubility measurements in choline chloride natural deep eutectic solvents, ccNADES, comprising one of seven of the following polyalcohols: glycerol, sorbitol, xylitol, glucose, sucrose, maltose and fructose. The ratio of ccNADES components was optimized for maximizing caffeine solubility at room temperature. Additionally, temperature dependent solubility was measured for the first four systems exhibiting the highest solubility potential, both in their neat forms and in mixtures with water. Results were used for intermolecular interactions assessments using the COSMO-RS-DARE approach, which led to a perfect match between experimental and computed solubility values. An important methodological discussion was provided for an appropriate definition of the systems. Surprising linear trends were observed between the values of fitting parameters and water-ccNADES composition. In addition, comments on selection of the values of the fusion thermodynamic parameters were provided, which led to the conclusion that COSMO-RS-DARE solubility computations can effectively compensate for the inaccuracies of these important physicochemical properties.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantification of Caffeine Interactions in Choline Chloride Natural Deep Eutectic Solvents: Solubility Measurements and COSMO-RS-DARE Interpretation

Jeliński¹,

Cysewski²

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Microneedle technologies have successfully delivered vaccines but are more complicated to manufacture and require microscopic penetration of the stratum corneum [59]. Proniosomal patches offer benefits over liposome-based TDDS, but are currently rudimentary and have not been shown to be effective with a wide variety of drugs [60,61]. Current technology in transdermal steroid delivery, outside of matrixbased patches, is currently comprised of liposome-mediated delivery and nanoparticle formulations [62,63].…”

Section: Discussionmentioning

confidence: 99%

Development and In Vitro Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Ramesh¹,

Zamat²,

Vadlamudi³

et al. 2022

J Drug Res Dev

View full text Add to dashboard Cite

Medication nonadherence results in avoidable symptom exacerbations and hospitalization, causing thousands of deaths and billions of dollars in healthcare costs annually. Although pharmacological therapies are present for chronic diseases, lengthy and complicated medication regimens often have high rates of nonadherence. Transdermal drug delivery is a potential method of reducing medication nonadherence as it allows for long-course medication regimens to be simplified to a one-time epidermal patch. We have engineered a transdermal drug delivery system on a customizable platform to longitudinally deliver a wide variety of soluble small-molecule drugs. As a proof of concept, we have chosen to administer long-course corticosteroids for chronic inflammatory disease via epidermal patch. A drug-in-adhesive matrix consisting of the drug, adhesive, solvents, and penetration enhancers, was cured onto a fluoropolymer release liner. The transdermal drug delivery system has an integrated tapering mechanism to avoid end-of-course steroid dependence and can incorporate other small-molecule medications required for cases of polypharmacy. To date, there have been no successful attempts to develop long-term steroid patches for systemic delivery, which may be attributed to issues with patch adhesion and skin irritation over extended periods of time. We have analyzed such challenges and have designed a proof of concept system to overcome these obstacles in order to provide patients with a simple, inexpensive, and effective solution to complicated and long-term treatment regimens.

show abstract

“…Microneedle technologies have successfully delivered vaccines but are more complicated to manufacture and require microscopic penetration of the stratum corneum [58]. Proniosomal patches offer bene ts over liposome-based TDDS, but are currently rudimentary and have not been shown to be effective with a wide variety of drugs [59], [60]. Current technology in transdermal steroid delivery, outside of matrix-based patches, is currently comprised of liposome-mediated delivery and nanoparticle formulations [61], [62].…”

Section: Discussionmentioning

confidence: 99%

Development and Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Ramesh

Zamat

Vadlamudi

et al. 2021

Preprint

View full text Add to dashboard Cite

Medication nonadherence results in avoidable symptom exacerbations and hospitalization, causing thousands of deaths and billions of dollars in healthcare costs annually. Although pharmacological therapies are present for chronic diseases, lengthy and complicated medication regimens often have high rates of nonadherence. Transdermal drug delivery is a potential method of reducing medication nonadherence as it allows for long-course medication regimens to be simplified to a one-time epidermal patch. We have engineered a transdermal drug delivery system on a customizable platform to longitudinally deliver a wide variety of soluble small-molecule drugs. As a proof of concept, we have chosen to administer long-course corticosteroids for chronic inflammatory disease via epidermal patch. The transdermal drug delivery system has an integrated tapering mechanism to avoid end-of-course steroid dependence and can incorporate other small-molecule medications required for cases of polypharmacy. To date, there have been no successful attempts to develop long-term steroid patches for systemic delivery which can be attributed to issues with patch adhesion and skin irritation over extended periods of time. We have analyzed such challenges and have designed a proof of concept system to overcome these obstacles in order to provide patients with a simple, inexpensive, and effective solution to complicated and long-term treatment regimens.

show abstract

Design and development of a proniosomal transdermal drug delivery system of caffeine for management of migraine: In vitro characterization, 131I-radiolabeling and in vivo biodistribution studies

Cited by 21 publications

References 59 publications

Quantification of Caffeine Interactions in Choline Chloride Natural Deep Eutectic Solvents: Solubility Measurements and COSMO-RS-DARE Interpretation

Quantification of Caffeine Interactions in Choline Chloride Natural Deep Eutectic Solvents: Solubility Measurements and COSMO-RS-DARE Interpretation

Development and In Vitro Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Development and Testing of a Novel Universal Transdermal Drug Delivery Platform to Reduce Medication Nonadherence

Contact Info

Product

Resources

About